LIFE SCIENCES & HEALTHCARE

• Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company, on its $74.8 million public offering, which included the underwriters’ full exercise of their option to purchase additional shares
• Butterfly Network, Inc. (NYSE: BFLY), a digital health company, on its $86.9 million public offering of its Class A common stock
• Lantheus Holdings, Inc. (NASDAQ: LNTH), a company focused on developing innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, in a Rule 144A offering of $575 million aggregate principal amount of its 2.625% convertible senior notes due 2027
• GreenLight Biosciences, a biotechnology company dedicated to making RNA products affordable and accessible for human health and agriculture, in a $1.2 billion SPAC business combination with Environmental Impact Acquisition Corp. that resulted in GreenLight becoming a publicly listed company.
• Applied Genetic Technologies Corp., a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases in several capital markets transactions, including:
  • An at-the-market offering (ATM) program having an aggregate offering price of up to $50 million, with Cantor Fitzgerald & Co.
  • Its underwritten public offering of 16,741,573 shares 
  • Its sales agreement with Cantor Fitzgerald & Co. for an up to $25 million ATM offering
  • Its $37.4 million underwritten public offering of common stock
  • Its $52 million IPO
• Biogen Inc., in several sophisticated debt finance transactions, including:
  • A registered offering of senior unsecured notes for an aggregate principal amount of $3 billion 
  • A cash tender offer and exchange offer for outstanding 5.200% senior notes totaling $1.75 billion
  • A senior unsecured syndicated credit facility for $1 billion
• Clinical stage biotechnology company Enanta Pharmaceuticals Inc., in its initial public offering of common stock.
• Organogenesis Holdings Inc., and its wholly owned subsidiary Organogenesis Inc., a leading regenerative medicine company, in several transactions, including:
  • Its $64.7 million underwritten public offering of Class A common stock
  • Its $50.3 million underwritten public offering of Class A common stock
  • Its warrant exchange offer and consent solicitation
  • A SPAC IPO/reverse merger of Organogenesis Inc., with and into a wholly owned subsidiary of Avista Healthcare Public Acquisition Corp., with Organogenesis Inc., surviving the merger and AHPAC changing its name to Organogenesis Holdings Inc.

TECHNOLOGY

• Leading industrial technology company Sensata Technologies in multiple financings, including:
  • The refinancing and amendments of its $1.45 billion syndicated senior secured revolving credit and term loan facilities
  • Its Rule 144A offering of $450 million senior notes
  • The amendments and consents obtained from lenders relating to approximately $3.7 billion of debt consisting of high-yield bonds and senior secured credit facilities
  • An indirect, wholly owned subsidiary of Sensata Technologies Holding in a Rule 144A offering of $750 million in aggregate principal amount of 3.750% senior notes due 2031.

CANNABIS

• The Valens Company (TSX: VLNS; Nasdaq: VLNS), a leading manufacturer of cannabis products, in its underwritten “bought deal” offering of units resulting in gross proceeds to the company of approximately CDN$32.3 million, including the exercise of the underwriters’ over-allotment option.
• Trulieve Cannabis Corp., a multistate cannabis operator, in several capital markets transactions including:
  • Its underwritten public offering of approximately US$228 million of subordinate voting shares
  • Its CDN$115.5 million offering of subordinate voting shares